| From laboratory to clinic: rationale for biologic therapy. | |
| | |
MedLine Citation:
|
PMID: 15450333 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Traditional systemic therapy for psoriasis is limited by either lack of efficacy or the long-term side effect profile of the medications used. Newer information about the pathophysiology of the disease has led to new perspectives on developing novel techniques for attacking psoriasis. This article discusses the pathogenesis of psoriasis, looks at the immunologic factors that contribute to forming a psoriatic plaque, reviews how novel biologic therapies are made, and explores how biologics can target each of these specific parts of the immunologic cascade. |
| | |
Authors:
|
Stephanie Mehlis; Kenneth B Gordon |
Related Documents
:
|
21063523 - Psoriasis and cardiomyopathy: an intriguing association. 17671883 - Measures used in specifying psoriasis lesion(s), global disease and quality of life: a ... 2845003 - Monoclonal antibody against polyglucosan isolated from the myocardium of a patient with... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Review |
Journal Detail:
|
Title: Dermatologic clinics Volume: 22 ISSN: 0733-8635 ISO Abbreviation: Dermatol Clin Publication Date: 2004 Oct |
Date Detail:
|
Created Date: 2004-09-28 Completed Date: 2004-10-26 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8300886 Medline TA: Dermatol Clin Country: United States |
Other Details:
|
Languages: eng Pagination: 371-7, vii-viii Citation Subset: IM |
Affiliation:
|
Department of Dermatology, Northwestern University Medical School, 675 N. St. Clair Street, Chicago, IL 60611, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Therapy
/
methods* Chronic Disease Combined Modality Therapy Drug Delivery Systems Female Humans Immunosuppressive Agents / administration & dosage* Immunotherapy / methods Male Prognosis Psoriasis / diagnosis*, immunology, therapy* Risk Assessment Severity of Illness Index T-Lymphocytes / drug effects* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current concepts in the immunopathogenesis of psoriasis.
Next Document: Quality-of-life issues in psoriasis.